IP Library Granted Patent US 9,650,346
Granted Patent B2
US 9,650,346 · App. 13/985,172 · Granted May 16, 2017

Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,346
App. No.
13/985,172
Granted
May 16, 2017
Kind
B2
Abstract

Disclosed are solid forms of antiretroviral compounds and anti-oxidative acids, and processes for their preparation. Pharmaceutical compositions using the solid forms are also disclosed.

Claims (13)

1. A composition comprising tenofovir disoproxil caffeate or tenofovir disoproxil p-coumarate wherein the tenofovir disoproxil caffeate is characterized by a 1:1 ratio of tenofovir and caffeic acid, and by an X-Ray diffraction pattern in accordance with FIG. 6 or FIG. 7 , and wherein the tenofovir disoproxil p-coumarate is characterized by X-Ray diffraction pattern in accordance with FIG. 8 .

2. A process for preparing a solid composition containing tenofovir disoproxil caffeate or tenofovir disoproxil p-coumarate, wherein the tenofovir disoproxil caffeate is characterized by a 1:1 ratio of tenofovir and caffeic acid and by an X-Ray diffraction pattern in accordance with FIG. 6 or FIG. 7 , and wherein the tenofovir disoproxil p-coumarate is characterized by an X-Ray diffraction pattern in accordance with FIG. 8 , comprising: mixing, in solution, the tenofovir disoproxil with either caffeic acid or p-coumaric acid under crystallization conditions sufficient to produce the solid composition.

3. The process according to claim 2 , wherein the mixing step further comprises:

a) dissolving the tenofovir disoproxil in a solvent at a temperature to produce a solution;

b) adding either caffeic acid or p-coumaric acid to the solution; and

c) isolating the solid composition from the solution.

4. The process according to claim 3 , wherein the solvent is selected from the group consisting of water, lower alcohols, ketones, esters, ethers, C 5-7 linear, branched or cyclic, saturated or unsaturated hydrocarbons, nitriles, halogenated hydrocarbons, and mixtures thereof.

5. The process according to claim 3 , wherein the solvent is selected from the group consisting of methanol, ethanol, isopropanol, acetone, tetrahydrofuran, isopropyl ether, acetonitrile, hexane, cyclohexane, ethyl acetate, water, and mixtures thereof.

6. The process according to claim 3 , further comprising:

adding a second solvent and cooling the solution to precipitation or concentrating the solution prior to step c).

7. The process according to claim 6 , wherein the second solvent is selected from the group consisting of water, ethers, cyclic hydrocarbons, and mixtures thereof.

8. The process according to claim 3 , wherein the temperature is about 30° C. to about reflux.

9. The process according to claim 3 , wherein the isolating step c) uses filtration.

Assignments (2)
CHANGE OF NAME Recorded Aug 11, 2017
From: LAURUS LABS PRIVATE LIMITED
To: LAURUS LABS LIMITED
Reel/Frame 043538/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: INDKURI, VENKATA S.; MUPPIDI, VAMSEE K.; JOGA, SREE R.; GORANTLA, SEETA R.; CHAVA, SATYANARAYANA
To: LAURUS LABS PRIVATE LTD.
Reel/Frame 031462/0063 →